U.S. markets closed
  • S&P Futures

    4,698.25
    -0.75 (-0.02%)
     
  • Dow Futures

    35,744.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    16,388.50
    -3.75 (-0.02%)
     
  • Russell 2000 Futures

    2,269.30
    -0.50 (-0.02%)
     
  • Crude Oil

    72.72
    +0.36 (+0.50%)
     
  • Gold

    1,784.70
    -0.80 (-0.04%)
     
  • Silver

    22.42
    -0.01 (-0.03%)
     
  • EUR/USD

    1.1339
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.5090
    +0.0290 (+1.96%)
     
  • Vix

    19.90
    -1.99 (-9.09%)
     
  • GBP/USD

    1.3202
    -0.0004 (-0.03%)
     
  • USD/JPY

    113.7400
    +0.0030 (+0.00%)
     
  • BTC-USD

    50,405.41
    -95.24 (-0.19%)
     
  • CMC Crypto 200

    1,320.29
    +15.18 (+1.16%)
     
  • FTSE 100

    7,337.05
    -2.85 (-0.04%)
     
  • Nikkei 225

    28,838.55
    -22.07 (-0.08%)
     

Ocular Therapeutix's Intravitreal Implant Shows Decrease In Retinal Fluid In Early-Stage Wet AMD Study

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Ocular Therapeutix Inc (NASDAQ: OCUL) on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal diseases. 

  • Ocular presented the data at the Angiogenesis, Exudations, and Degeneration 2021 Meeting.

  • OTX-TKI is an axitinib intravitreal implant for the treatment of wet age-related macular degeneration (AMD).

  • Interim data showed that some subjects showed a decrease in the intraretinal or subretinal fluid by two months in Cohorts 2 (400 µg) & 3a (600 µg). While the combination of OTX-TKI and Anti-VEGF in Cohort 3b showed a decrease immediately, as early as a week after treatment in two subjects.

  • Some subjects demonstrated the durability of therapy for up to 10 months, and one subject demonstrated durability to 13.5 months in cohort 2 (400 µg).

  • One subject in cohort 3a (600 µg) demonstrated the durability of therapy for up to 6 months.

  • The implant was biodegraded in all subjects in Cohort 1 by 9-10.5 months.

  • OTX-TKI was generally well tolerated, with a favorable safety profile, and no ocular serious adverse events were observed. 

  • Take a look at the presentation here.

  • Price Action: OCUL closed 1.92% down at $19.38 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.